Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia.

20 Jan 2015

Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on strategies for prescribing drugs to manage obesity and promote weight loss.

16 Jan 2015

Some medicines can make skin sun-sensitive, says NPS MedicineWise clinical adviser

Some medicines can make your skin more sensitive to the sun and this summer season NPS MedicineWise advises Australians to check their medicines packaging for warnings to avoid excessive skin exposure to sunlight and sunlamps.

9 Jan 2015

Longitudinal course of schizophrenia negative symptoms revealed

Schizophrenia negative symptoms are relatively stable in the first year for most patients after they begin antipsychotic medication but research suggests around a quarter will experience exacerbation or relapse.

7 Jan 2015

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

6 Jan 2015

Antipsychotic polypharmacy prevalent despite efficacy doubts

Results of a retrospective study suggest that around a quarter of patients with schizophrenia receive antipsychotic polypharmacy, despite a lack of evidence for the approach.

17 Dec 2014

Novel drug target could lead to better antipsychotic medications

Scientists at the Centre for Addiction and Mental Health have identified a novel drug target that could lead to the development of better antipsychotic medications.

10 Dec 2014

Excess mortality in schizophrenia ‘not attributable to antipsychotics’

The relationship between antipsychotic use and mortality in people with schizophrenia shows a clear U-shape curve, with the highest risk of death seen in those with no antipsychotic exposure, a Swedish cohort study has found.

9 Dec 2014

People with first-episode psychosis may benefit from medication treatment changes, study finds

Many patients with first-episode psychosis receive medications that do not comply with recommended guidelines for first-episode treatment, researchers have found. Current guidelines emphasize low doses of antipsychotic drugs and strategies for minimizing the side effects that might contribute to patients stopping their medication.

5 Dec 2014

Lewy body dementia: 10 things people need to know

The recent news that the brain of actor/comedian Robin Williams showed signs of diffuse Lewy body disease has created more interest and coverage in this widely under-diagnosed condition than ever before.

25 Nov 2014

Successful antipsychotic treatment may alter striatal connectivity

Connectivity within the striatum changes as psychotic symptoms improve in patients treated with second-generation antipsychotics, a study shows.

20 Nov 2014

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults.

19 Nov 2014

Schizophrenia symptom severity predicts atypical antipsychotic benefit

Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry.

12 Nov 2014

Metabolic syndrome screening in bipolar disorder warranted

The frequency of the metabolic syndrome in patients with bipolar disorder warrants systematic screening, say researchers, particularly among men, older patients and those receiving atypical antipsychotic treatment.

12 Nov 2014

Physical health management below par in schizophrenia patients

The diagnosis and treatment of physical ailments in patients with schizophrenia falls below acceptable standards, shows a national audit of patients in England and Wales.

30 Oct 2014

Study finds that mental health disorders double heart disease, stroke risks

People facing mental health challenges are significantly more likely to have heart disease or stroke, according to a study presented today at the Canadian Cardiovascular Congress.

28 Oct 2014

$Insulin resistance linked to treatment-refractory bipolar disorder$

Insulin resistance linked to treatment-refractory bipolar disorder

Patients with bipolar disorder who are insulin resistant are likely to also be refractory to mood-stabilising treatment, report researchers.

22 Oct 2014

Changing placebo response dilutes antipsychotic trial power

Factors including patients’ expectations may underlie an increased placebo response in antipsychotic randomised controlled trials published since 1960, say researchers.

22 Oct 2014

Aspirin can improve efficacy of schizophrenia treatments

A new study shows that some anti-inflammatory medicines, such as aspirin, estrogen, and Fluimucil, can improve the efficacy of existing schizophrenia treatments. This work is being presented at the European College of Neuropsychopharmacology conference in Berlin.

20 Oct 2014